robert r nesbitt (44 risultati)

Soft cover. Condizione: Near Fine. No Jacket. Color cover illustration by Duncan Eaglesson (illustratore). 1st Edition. Three issues (the third a "Special Double," and apparently the final issue of this fiction and poetry quarterly, based in Providence, R.I.) This periodical's ISSN -- which the ABE computer doesn't like -- is 0198-6945. Mystery, fantasy, suspense, Gothic; poetry. The three softcover 12mos totaling, respectively, 112, 112, and 184 pp. The group of three issues now reduced from $32.

Hardcover. Condizione: Used - Very Good. Harvard University Press, Cambridge, 1968. 388 pages. Illustrated. 9.5 x 6.5", hardcover, no dj. No dj, clean, tight, Very Good/None.

hardcover. Condizione: Fine.

hardcover. Condizione: Very Good.

Hardcover. Condizione: Fine. Condizione sovraccoperta: Fine. First Edition.

Hardcover. 1st Edition. 388 Seiten Good condition. Reading pages are clean and without marks. Retired library exemplar, with the usual marking. Corners slightly rubbed or bumped. 9780674453012 Sprache: Englisch Gewicht in Gramm: 770.

Hardcover. Condizione: new. Hardcover. This open access book builds the case for the business motivation, techniques, and approaches to use in development of a medicinal product for human therapy, whether delivered via an oral dose form (pill or solution) or a delivery system (device). It shares the growing demands by patients and caregivers, as well as regulators, for designs which are most easily understood and usable, and which can ensure the medication can be consistently delivered and will, therefore, allow best outcomes. The book weaves skills in human-centered design into the design of medicinal delivery systems. It would be a reference for those in academia studying pharmacokinetics, formulation or product design and development, as well as those in the development of biopharmaceutical therapies. This is an open access book. This open access book builds the case for the business motivation, techniques, and approaches to use in development of a medicinal product for human therapy, whether delivered via an oral dose form (pill or solution) or a delivery system (device). Shipping may be from multiple locations in the US or from the UK, depending on stock availability.

Condizione: New.

Condizione: New.

Hardcover. Condizione: Brand New. 149 pages. 9.26x6.11x9.25 inches. In Stock.

Buch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - This open access book builds the case for the business motivation, techniques, and approaches to use in development of a medicinal product for human therapy, whether delivered via an oral dose form ('pill' or solution) or a delivery system (device). It shares the growing demands by patients and caregivers, as well as regulators, for designs which are most easily understood and usable, and which can ensure the medication can be consistently delivered and will, therefore, allow best outcomes. The book weaves skills in 'human-centered design' into the design of medicinal delivery systems. It would be a reference for those in academia studying pharmacokinetics, formulation or product design and development, as well as those in the development of biopharmaceutical therapies. This is an open access book.

Condizione: New.

Hardcover. Condizione: new. Hardcover. This open access book builds the case for the business motivation, techniques, and approaches to use in development of a medicinal product for human therapy, whether delivered via an oral dose form (pill or solution) or a delivery system (device). It shares the growing demands by patients and caregivers, as well as regulators, for designs which are most easily understood and usable, and which can ensure the medication can be consistently delivered and will, therefore, allow best outcomes. The book weaves skills in human-centered design into the design of medicinal delivery systems. It would be a reference for those in academia studying pharmacokinetics, formulation or product design and development, as well as those in the development of biopharmaceutical therapies. This is an open access book. This open access book builds the case for the business motivation, techniques, and approaches to use in development of a medicinal product for human therapy, whether delivered via an oral dose form (pill or solution) or a delivery system (device). Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability.

Condizione: New.

Condizione: New. In.

Condizione: New. In.

Condizione: New.

Condizione: As New. Unread book in perfect condition.

Condizione: As New. Unread book in perfect condition.

Kartoniert / Broschiert. Condizione: New.

Gebunden. Condizione: New.

Paperback. Condizione: New. 2020 ed.

Condizione: Hervorragend. Zustand: Hervorragend | Seiten: 912 | Sprache: Englisch | Produktart: Bücher | The biotechnology/biopharmaceutical sector has tremendously grown which led to the invention of engineered antibodies such as Antibody Drug Conjugates (ADCs), Bispecific T-cell engager (BITES), Dual Variable Domain (DVD) antibodies, and fusion proteins that are currently being used as therapeutic agents for immunology, oncology and other disease conditions. Regulatory agencies have raised the bar for the development and manufacture of antibody-based products, expecting to see the use of Quality by Design (QbD) elements demonstrating an in-depth understanding of product and process based on sound science. Drug delivery systems have become an increasingly important part of the therapy and most biopharmaceuticals for self-administration are being marketed as combination products. A survey of the market indicates that there is a strong need for a new book that will provide ¿one stop shopping¿ for the latest information and knowledge of the scientific and engineering advances madeover the last few years in the area of biopharmaceutical product development. The new book entitled Development of Biopharmaceutical Drug Device Products is a reference text for scientists and engineers in the biopharmaceutical industry, academia or regulatory agencies. With insightful chapters from experts in the field, this new book reviews first principles, covers recent technological advancements and provides case studies and regulatory strategies relating to the development and manufacture of antibody-based products. It covers topics such as the importance of early preformulation studies during drug discovery to influence molecular selection for development, formulation strategies for new modalities, and the analytical techniques used to characterize them. It also addresses important considerations for later stage development such as the development of robust formulations and processes, including process engineering and modeling of manufacturing unit operations, the design of analytical comparability studies, and characterization of primary containers (pre-filled syringes and vials).Finally, the latter half of the book reviews key considerations to ensure the development and approval of a patient-centered delivery system design. This involves the evolving regulatory framework with perspectives from both the US and EU industry experts, the role of international standards, design control/risk management, human factors and its importance in the product development and regulatory approval process, as well as review of the risk-based approach to bridging between devices used in clinical trials and the to-be-marketed device. Finally, case studies are provided throughout.The typical readership would have biology and/or engineering degrees and would include researchers, scientific leaders, industry specialists and technology developers working in the biopharmaceutical field.

Taschenbuch. Condizione: Neu. Development of Biopharmaceutical Drug-Device Products | Feroz Jameel (u. a.) | Taschenbuch | AAPS Advances in the Pharmaceutical Sciences Series | xviii | Englisch | 2021 | Springer | EAN 9783030314170 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.

Paperback. Condizione: New. 1st ed. 2020.

Buch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - The biotechnology/biopharmaceutical sector has tremendously grown which led to the invention of engineered antibodies such as Antibody Drug Conjugates (ADCs), Bispecific T-cell engager (BITES), Dual Variable Domain (DVD) antibodies, and fusion proteins that are currently being used as therapeutic agents for immunology, oncology and other disease conditions. Regulatory agencies have raised the bar for the development and manufacture of antibody-based products, expecting to see the use of Quality by Design (QbD) elements demonstrating an in-depth understanding of product and process based on sound science. Drug delivery systems have become an increasingly important part of the therapy and most biopharmaceuticals for self-administration are being marketed as combination products. A survey of the market indicates that there is a strong need for a new book that will provide 'one stop shopping' for the latest information and knowledge of the scientific and engineering advances madeover the last few years in the area of biopharmaceutical product development. The new book entitled Development of Biopharmaceutical Drug Device Products is a reference text for scientists and engineers in the biopharmaceutical industry, academia or regulatory agencies.With insightful chapters from experts in the field, this new book reviews first principles, covers recent technological advancements and provides case studies and regulatory strategies relating to the development and manufacture of antibody-based products. It covers topics such as the importance of early preformulation studies during drug discovery to influence molecular selection for development, formulation strategies for new modalities, and the analytical techniques used to characterize them. It also addresses important considerations for later stage development such as the development of robust formulations and processes, including process engineering and modeling of manufacturing unit operations, the design of analytical comparability studies, and characterization of primary containers (pre-filled syringes and vials).Finally, the latter half of the book reviews key considerations to ensure the development and approval of a patient-centered delivery system design. This involves the evolving regulatory framework with perspectives from both the US and EU industry experts, the role of international standards, design control/risk management, human factors and its importance in the product development and regulatory approval process, as well as review of the risk-based approach to bridging between devices used in clinical trials and the to-be-marketed device. Finally, case studies are provided throughout.The typical readership would have biology and/or engineering degrees and would include researchers, scientific leaders, industry specialists and technology developers working in the biopharmaceutical field.

Taschenbuch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - The biotechnology/biopharmaceutical sector has tremendously grown which led to the invention of engineered antibodies such as Antibody Drug Conjugates (ADCs), Bispecific T-cell engager (BITES), Dual Variable Domain (DVD) antibodies, and fusion proteins that are currently being used as therapeutic agents for immunology, oncology and other disease conditions. Regulatory agencies have raised the bar for the development and manufacture of antibody-based products, expecting to see the use of Quality by Design (QbD) elements demonstrating an in-depth understanding of product and process based on sound science. Drug delivery systems have become an increasingly important part of the therapy and most biopharmaceuticals for self-administration are being marketed as combination products. A survey of the market indicates that there is a strong need for a new book that will provide 'one stop shopping' for the latest information and knowledge of the scientific and engineering advances madeover the last few years in the area of biopharmaceutical product development. The new book entitled Development of Biopharmaceutical Drug Device Products is a reference text for scientists and engineers in the biopharmaceutical industry, academia or regulatory agencies.With insightful chapters from experts in the field, this new book reviews first principles, covers recent technological advancements and provides case studies and regulatory strategies relating to the development and manufacture of antibody-based products. It covers topics such as the importance of early preformulation studies during drug discovery to influence molecular selection for development, formulation strategies for new modalities, and the analytical techniques used to characterize them. It also addresses important considerations for later stage development such as the development of robust formulations and processes, including process engineering and modeling of manufacturing unit operations, the design of analytical comparability studies, and characterization of primary containers (pre-filled syringes and vials).Finally, the latter half of the book reviews key considerations to ensure the development and approval of a patient-centered delivery system design. This involves the evolving regulatory framework with perspectives from both the US and EU industry experts, the role of international standards, design control/risk management, human factors and its importance in the product development and regulatory approval process, as well as review of the risk-based approach to bridging between devices used in clinical trials and the to-be-marketed device. Finally, case studies are provided throughout.The typical readership would have biology and/or engineering degrees and would include researchers, scientific leaders, industry specialists and technology developers working in the biopharmaceutical field.

Paperback. Condizione: Brand New. 911 pages. 9.25x6.10x1.80 inches. In Stock.

Hardcover. Condizione: Brand New. 911 pages. 9.25x6.10x2.05 inches. In Stock.

Hardcover. Condizione: gut. 2020. Development of Biopharmaceutical Drug-Device Products In deutscher Sprache. pages.